A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• MYCN oncogene drives aggressive tumor behavior and chemotherapy resistance.
• Targeting MYCN directly is clinically unfeasible, necessitating exploration of alternative vulnerabilities.
• Previous work showed PARP inhibitors increase MYCN-driven replication stress, countered by CHK1.

Purpose of the Study:

• To investigate the synergistic effects of combining PARP and CHK1 inhibitors in MYCN-driven tumors.
• To evaluate this combination as a potential chemo-free therapeutic strategy.
• To determine the efficacy and safety of this drug combination in preclinical models.

Main Methods:

• Utilized neuroblastoma cell lines and SHH-medulloblastoma primary cultures.
• Employed PARP inhibitors (olaparib) and CHK1 inhibitors (MK-8776).
• Assessed drug synergy, DNA damage, cell death, and tumor growth in vitro and in vivo models. CRISPR/Cas9 was used to correct ATM mutation.

Main Results:

• PARP and CHK1 inhibitors synergized to induce cell death, particularly in MYCN-amplified/overexpressing cells.
• The combination led to MYCN-dependent DNA damage accumulation and cell death in vitro.
• Significant reduction in tumor growth was observed in four in vivo models of MYCN-driven tumors with minimal toxicity.

Conclusions:

• Combination of PARP and CHK1 inhibitors is a potent chemo-free strategy against MYCN-driven cancers.
• This approach warrants prompt translation into clinical trials for MYCN-driven tumor treatment.
• The efficacy is linked to MYCN status, not ATM mutation, suggesting broad applicability.